Octreotide
FDA-approved somatostatin analog — Sandostatin / LAR (long-acting release) / Mycapssa.
What it's for
FDA-approved somatostatin analog — Sandostatin / LAR (long-acting release) / Mycapssa.
What it's for
Octreotide is a synthetic 8–amino-acid peptide somatostatin analog available as short-acting injection, long-acting LAR (long-acting release), and oral capsules (Mycapssa) for selected indications. It reduces symptoms of carcinoid syndrome and VIPomas (rare VIP-secreting tumors), treats acromegaly in appropriate patients, and has other labeled specialty uses.
What it does for the body
It reduces symptoms of carcinoid syndrome and VIPomas (rare VIP-secreting tumors), treats acromegaly in appropriate patients, and has other labeled specialty uses. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
Somatostatin receptors (lock-and-key landing spots on cells) activating its target pathway suppresses pathologic hormone secretion (growth hormone, serotonin, VIP, etc.). Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Octreotide has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Digestive research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Octreotide — FDA.gov search
- ClinicalTrials.gov search: Octreotide — U.S. clinical trials registry
- Drugs@FDA search: Octreotide — FDA drug database (if approved)
- PubMed search: Octreotide — NCBI PubMed
- PubMed Central search: Octreotide — NCBI PMC